Yinhu Qingwen Granule in the Treatment of Viral Pneumonia

Browse trials for

• Pneumonia 2,044
• Pneumonia, Viral 144

Pneumonia

2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.

This study's planned enrollment of 60 is below the median of 106 across 1,247 interventional studies indexed under Pneumonia.

Lead sponsor

Zhong Wang is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Study arms

• Experimental
  Yinhu Qingwen Granule

  For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day. All treatment should be used for 10 days unless all the symtopms of patient with the viral pneumonia are relieved.

  Drug: Yinhu Qingwen Granules

Interventions

• DrugYinhu Qingwen Granules

  For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.

Primary outcomes

1. Time to the normalization of the temperature

   The normalization of the temperature is defined as that the temperature of the patient dropped to normal and stabilized for more than 72 hours.

   Time frame: up to 30 days

Secondary outcomes

1. Time to cough reported as mild or absent

   The severity of cough is assessed using Cough Symptom Scale, a scale range from 0-6. 0: cough absent;1-2: mild; 3-4:moderate; 5-6: severe

   Time frame: Baseline, Day 3, Day 7, Day 10 and Day 30

2. Mean clinical recovery time (hours)

   The clinical recovery time is defined as the time from initiation of study treatment (active or placebo) until normalisation of fever, respiratory rate, and oxygen saturation, and alleviation of cough, sustained for at least 72 hours. Normalisation and alleviation criteria: (1) Fever: ≤36.6°C or -axilla, ≤37.2 °C oral or ≤37.8°C rectal or tympanic;(2)Respiratory rate - ≤24/minute on room air; 3) Oxygen saturation - \>94% on room air; (4) Cough - mild or absent on a patient reported scale (cough symptoms score ≤ 2 points).

   Time frame: up to 30 days

3. Time to dyspnea reported as mild or absent

   The severity of dyspnea is assessed on a self-reported scale of severe, moderate, mild or absent.

   Time frame: Baseline, Day 3, Day 7, Day 10 and Day 30

4. Mean blood oxygen saturation

   Time frame: Baseline, Day 3, Day 7, Day 10

5. Mean neutrophil/lymphocyte ratio (NLR)

   Neutrophil/lymphocyte ratio (NLR) is obtained from the blood routine.

   Time frame: Baseline, Day 10

6. Frequency of requirement for supplemental oxygen or non-invasive ventilation

   Time frame: up to 30 days

7. Mean time of supplemental oxygen (days)

   Time frame: up to 30 days

8. Mean time of non-invasive ventilation (days)

   Time frame: up to 30 days

9. Severe case incidence

   Severe case is defined as respiratory rate ≥30/minute on room air；or Oxygen saturation - ≤94% on room air；or PaO2/FiO2≤300mmHg.

   Time frame: up to 30 days

10. Proportion of re-hospitalization or admission to ICU

    Time frame: up to 30 days

11. All-cause mortality

    Time frame: up to 30 days

12. Frequency of serious adverse events

    Time frame: up to 30 days